JP7383605B2 - 抗ｐｄ－ｌ１抗体とその作製及び使用方法 - Google Patents

抗ｐｄ－ｌ１抗体とその作製及び使用方法 Download PDF

Info

Publication number
JP7383605B2
JP7383605B2 JP2020520424A JP2020520424A JP7383605B2 JP 7383605 B2 JP7383605 B2 JP 7383605B2 JP 2020520424 A JP2020520424 A JP 2020520424A JP 2020520424 A JP2020520424 A JP 2020520424A JP 7383605 B2 JP7383605 B2 JP 7383605B2
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
antibody
cancer
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020520424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530776A5 (https=
JP2020530776A (ja
JPWO2019005634A5 (https=
Inventor
ブライアン コヴァセヴィチ，
ドン シア，
アン イー． ジェンセン，
ジョナサン ケー． ファレン，
ブレア レンショー，
ジェフリー ビー． アダモ，
フィル タン，
ゼレン ガオ，
イ ツー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Systimmune Inc
Original Assignee
Systimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systimmune Inc filed Critical Systimmune Inc
Publication of JP2020530776A publication Critical patent/JP2020530776A/ja
Publication of JP2020530776A5 publication Critical patent/JP2020530776A5/ja
Publication of JPWO2019005634A5 publication Critical patent/JPWO2019005634A5/ja
Priority to JP2023190606A priority Critical patent/JP7610680B2/ja
Application granted granted Critical
Publication of JP7383605B2 publication Critical patent/JP7383605B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020520424A 2017-06-25 2018-06-22 抗ｐｄ－ｌ１抗体とその作製及び使用方法 Active JP7383605B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023190606A JP7610680B2 (ja) 2017-06-25 2023-11-08 抗ｐｄ－ｌ１抗体とその作製及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762524553P 2017-06-25 2017-06-25
US62/524,553 2017-06-25
PCT/US2018/039144 WO2019005634A2 (en) 2017-06-25 2018-06-22 ANTI-PD-L1 ANTIBODIES AND METHODS OF PREPARATION AND USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023190606A Division JP7610680B2 (ja) 2017-06-25 2023-11-08 抗ｐｄ－ｌ１抗体とその作製及び使用方法

Publications (4)

Publication Number Publication Date
JP2020530776A JP2020530776A (ja) 2020-10-29
JP2020530776A5 JP2020530776A5 (https=) 2022-01-17
JPWO2019005634A5 JPWO2019005634A5 (https=) 2022-01-17
JP7383605B2 true JP7383605B2 (ja) 2023-11-20

Family

ID=64742649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520424A Active JP7383605B2 (ja) 2017-06-25 2018-06-22 抗ｐｄ－ｌ１抗体とその作製及び使用方法
JP2023190606A Active JP7610680B2 (ja) 2017-06-25 2023-11-08 抗ｐｄ－ｌ１抗体とその作製及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023190606A Active JP7610680B2 (ja) 2017-06-25 2023-11-08 抗ｐｄ－ｌ１抗体とその作製及び使用方法

Country Status (5)

Country Link
US (1) US11560431B2 (https=)
EP (1) EP3645738A4 (https=)
JP (2) JP7383605B2 (https=)
CN (2) CN116535508A (https=)
WO (1) WO2019005634A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020098785A1 (zh) * 2018-11-16 2020-05-22 南京金斯瑞生物科技有限公司 人源化抗人pd-l1单克隆抗体及其制备方法和用途
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
EP4118120A4 (en) 2020-03-12 2024-04-17 Immune-ONC Therapeutics, Inc. NOVEL ANTI-LILRB4 ANTIBODIES AND DERIVATIVE PRODUCTS
BR112023016025A2 (pt) * 2021-02-10 2023-10-31 Jiangxi Jemincare Group Co Ltd Anticorpo anti-pd-l1 e uso dos mesmos
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016079050A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
JP2016525117A (ja) 2013-07-16 2016-08-22 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びｔｉｇｉｔ阻害剤を使用するがんの治療方法
WO2016196381A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer
JP2017501157A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
AU2009333580B2 (en) * 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
HRP20201595T1 (hr) * 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
CN116948035A (zh) * 2017-06-25 2023-10-27 西雅图免疫公司 多特异性抗体及其制备和使用方法
KR102785809B1 (ko) * 2017-11-02 2025-03-26 시스트이뮨, 인코포레이티드 이중특이성 항체 및 이의 제조 및 사용 방법
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525117A (ja) 2013-07-16 2016-08-22 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びｔｉｇｉｔ阻害剤を使用するがんの治療方法
JP2017501157A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法
WO2016079050A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
WO2016196381A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Pd-l1 promoter methylation in cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Frontiers in Oncology，2016, Vol.6, No.233, pp.1-16

Also Published As

Publication number Publication date
JP2024023249A (ja) 2024-02-21
JP7610680B2 (ja) 2025-01-08
US20220002417A1 (en) 2022-01-06
WO2019005634A2 (en) 2019-01-03
CN110831972A (zh) 2020-02-21
CN110831972B (zh) 2023-05-12
EP3645738A2 (en) 2020-05-06
JP2020530776A (ja) 2020-10-29
CN116535508A (zh) 2023-08-04
US11560431B2 (en) 2023-01-24
EP3645738A4 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
JP7464764B2 (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
JP7490109B2 (ja) 抗ｐｄ－１抗体とその作製及び使用方法
JP7610680B2 (ja) 抗ｐｄ－ｌ１抗体とその作製及び使用方法
JP7164596B2 (ja) 抗ｃｄ３抗体とその作製及び使用方法
US20250376531A9 (en) Anti-4-1bb antibodies and methods of making and using thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231108

R150 Certificate of patent or registration of utility model

Ref document number: 7383605

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350